Student
Nektar Therapeutics is a biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. The Companys product pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. Nektars research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. It creates its drug candidates by using its chemistry platform to modify the chemical structure of drugs using polymer conjugates. Nektars drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.
I invest in growing, profitable businesses with Mistral Equity Partners, a private equity firm with a targeted focus on consumer companies including food, beverage, consumer products, restaurants and retail. I have prior investment banking experience at J.P. Morgan advising Media & Telecom companies on their complex financing requirements, ongoing business operations, and the sale or purchase of businesses. These experiences have allowed me to develop a strong passion for both private and public investing.
Anymail finder is trusted by tens of thousands of companies to provide accurate contact information to their Sales and Business Development teams.
If you're looking to find the email of Kellen Wilkins at Nektar Therapeutics then you've come to the right place.
Wondering if it's kellen@nektar.com, kellen.wilkins@nektar.com, wilkins@nektar.com, or kwilkins@nektar.com? We have the answers for you.